Drug Trial Radar · NCT07326813
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
477
Planned (sponsor's estimate)
Start
Jan 12, 2026
Primary completion
Jul 12, 2027
Study completion Dec 3, 2027
Sponsor
- Lead sponsor
- InventisBio Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis. Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period. During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.
Conditions
- Plaque Psoriasis
Interventions
D-2570 TabletDrug
D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain
BMS-986165 TabletDrug
BMS-986165 is a novel inhibitor targeting TYK2
PlaceboDrug
A placebo refers to a tablet that has no therapeutic effect on medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasisTime frame: Treatment for 16 weeks after enrollment
- To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasisTime frame: Treatment for 16 weeks after enrollment
- To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasisTime frame: Treatment for 16 weeks after enrollment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.